LeMaitre Vascular, Inc. $LMAT Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. grew its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 292.3% in the 1st quarter, Holdings Channel reports. The firm owned 171,838 shares of the medical instruments supplier’s stock after acquiring an additional 128,033 shares during the quarter. Bessemer Group Inc.’s holdings in LeMaitre Vascular were worth $18,759,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Annex Advisory Services LLC boosted its position in LeMaitre Vascular by 6.0% during the 4th quarter. Annex Advisory Services LLC now owns 243,709 shares of the medical instruments supplier’s stock valued at $19,765,000 after purchasing an additional 13,692 shares during the period. Tudor Investment Corp ET AL acquired a new stake in LeMaitre Vascular in the third quarter worth $6,056,000. Wakefield Asset Management LLLP acquired a new stake in LeMaitre Vascular in the fourth quarter worth $1,130,000. Kennedy Capital Management LLC lifted its stake in LeMaitre Vascular by 14.8% in the fourth quarter. Kennedy Capital Management LLC now owns 247,907 shares of the medical instruments supplier’s stock valued at $20,105,000 after buying an additional 32,040 shares during the last quarter. Finally, Congress Asset Management Co. lifted its stake in LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,453 shares of company stock valued at $5,906,174 over the last quarter. Corporate insiders own 7.40% of the company’s stock.

Analysts Set New Price Targets

LMAT has been the subject of several recent research reports. Barrington Research restated an “outperform” rating and set a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Wells Fargo & Company upped their target price on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Stock Performance

LMAT stock opened at $101.63 on Friday. The company has a 50-day simple moving average of $97.00 and a 200 day simple moving average of $98.42. The company has a market capitalization of $2.32 billion, a P/E ratio of 37.50, a PEG ratio of 2.82 and a beta of 0.52. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a fifty-two week low of $79.00 and a fifty-two week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter last year, the company earned $0.48 EPS. LeMaitre Vascular’s quarterly revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.90%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.